ArticleClinical & translational immunology2023

JAK1/2 inhibitor ruxolitinib promotes the expansion and suppressive action of polymorphonuclear myeloid-derived suppressor cells via the JAK/STAT and ROS-MAPK/NF-κB signalling pathways in acute graft-versus-host disease.

Yigeng Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.